

Company Announcement
No. 8/2014

Results of election of employee elected member of Zealand's Board of Directors

Copenhagen, 16 April 2014 – Zealand Pharma A/S (Zealand) (NASDAQ OMX Copenhagen: ZEAL), announces that Jens Peter Stenvang, Senior Application Specialist, has been elected as the third employee elected member of the company's Board of Directors. Jens Peter Stenvang, (1954) is a qualified laboratory technician and he has been employed at Zealand since 2010.

Jens Peter Stenvang's appointment is for a four-year period and takes effect following Zealand's Annual General Meeting to be held on Tuesday, 29 April 2014, where he will replace Hanne Heidenheim Bak following completion of her term on the Board. The two other employee elected members of the Board of Directors have also been appointed for four-year periods, which will complete at the company's Annual General Meeting in 2016.

As first, second, third and fourth substitute employee representatives, the following have been elected: Søren Vitfell Keller, Head of Legal Affairs, Hanne Heidenheim Bak, Senior Director, Maria Juul Kolding, Manager of Documentation and Helle Haxgart, Accountant.

For further information, please contact:

David Solomon, President and Chief Executive Officer, Tel: +45 2220 6300

Hanne Leth Hillman, Vice President, Head of Investor Relations & Corporate Communications - Tel: +45 50 60 36 89, email: hlh@zealandpharma.com

About Zealand Pharma

Zealand Pharma A/S (NASDAQ OMX Copenhagen: ZEAL) ("Zealand") is a biotechnology company based in Copenhagen, Denmark. Zealand specializes in the discovery, optimization and development of novel peptide drugs and has a broad and mature pipeline of drug candidates identified through its own drug discovery activities. The company's focus lies in the field of cardio-metabolic diseases, diabetes and obesity in particular, and its lead drug invention is lixisenatide, a once-daily prandial GLP-1 agonist, which is licensed to



Sanofi for the treatment of Type 2 diabetes. Lixisenatide (marketed by Sanofi as Lyxumia®) is approved in several countries globally, including Europe and Japan. In the U.S., an NDA is planned to be submitted in 2015, after completion of the ELIXA Cardiovascular outcome study. In February 2014, Sanofi started the pivotal Phase 3 clinical program for the Lantus®/Lyxumia® combination product (LixiLan).

Zealand has a partnering strategy for the development and commercialization of its products and, in addition to the license agreement with Sanofi in Type 2 diabetes, the company has partnerships with Boehringer Ingelheim in diabetes/obesity, Lilly in diabetes and obesity, Helsinn Healthcare in chemotherapy induced diarrhea and AbbVie in acute kidney injury.

For further information: **zealandpharma.com**

Follow us on Twitter @ZealandPharma